An analysis of the costs and treatment success of etanercept in Juvenile Idiopathic Arthritis
François Prince(Hôpital du Sacré-Cœur de Montréal), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), R. ten Cate(Leiden University), Y. Koopman-Keemink(Juliana Kinderziekenhuis), Hein Raat(Erasmus MC), Simone Gorter(University Medical Center Groningen), Marion A. J. van Rossum(Reade), Esther P A H Hoppenreijs(Radboud University Nijmegen), E. W. de Bekker‐Grob(Radboud University Nijmegen), Marinka Twilt(University of Calgary)
Data Archiving and Networked Services (DANS)
April 30, 2011
Cited by 1
Related Papers
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative
|Health and Quality of Life Outcomes|2013|168
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based survey
|Arthritis Care & Research|2012|155